Fingerprint
Dive into the research topics where Fang-Shu Ou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)
Strosberg, J. R., Zemla, T., Geyer, S., Pulsipher, S., Ou, F. S., Behr, S., Raj, N., Vijayvergia, N., Dasari, A., O’Reilly, E. M., Meyerhardt, J. A., Wolin, E. M., Halfdanarson, T. R. & Chan, J. A., Jan 2026, In: Endocrine-Related Cancer. 33, 1, e250415.Research output: Contribution to journal › Article › peer-review
-
Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease
Allen, A. M., Kim, W. R., Carrieri, P., Canning, R., Ou, F. S., Benson, J., Olson, J. L., Venkatesh, S. K., Li, J., Yin, M., Eslami, M., Ehman, R. L., Ehman, R. & Lazarus, J. V., Feb 2026, In: Hepatology. 83, 2, p. 362-373 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
Wheless, M. C., Zemla, T. J., Hubbard, J. M., Strickler, J. H., Gbolahan, O. B., Wilson, L., Waechter, B., Ou, F. S., Nixon, A. B., Bekaii-Saab, T. S. & Ciombor, K. K., Jun 1 2025, In: Oncologist. 30, 6, oyaf069.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: Quantitative metrics of bone quality determined at the distal radius using photon-counting CT (Skeletal Radiology, (2025), 54, 3, (531-540), 10.1007/s00256-024-04770-9)
Dutta, A., Ferrero, A., Rajendran, K., Drake, M. T., Ou, F., Giri, S., Fletcher, J. G., McCollough, C. H. & Baffour, F. I., Mar 2025, In: Skeletal Radiology. 54, 3, p. 541-542 2 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades
Jamal, F., Sahvan, O., Uson, P. L. S., Jones, J. C., Ou, F. S., Bekaii-Saab, T. & Sonbol, M. B., Dec 1 2025, In: Oncologist. 30, 12, oyaf381.Research output: Contribution to journal › Article › peer-review
Open Access